Stockhub

Arcellx, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

26 July 2022

  • curprev 13:0113:01, 26 July 2022‎ Chris talk contribs‎ 872 bytes +872‎ Created page with "Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BC..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Arcellx,_Inc.’